KMID vs. BBC

Last updated Aug 5, 2026

KMID (Virtus KAR Mid-Cap ETF) and BBC (Virtus LifeSci Biotech Clinical Trials ETF) are both exchange-traded funds - KMID is a Mid Cap Growth Equities fund actively managed by Virtus, while BBC is a Health & Biotech Equities fund tracking the LifeSci Biotechnology Clinical Trials Index. KMID is actively managed, while BBC is passively managed. Over the past year, KMID returned 3.51% vs 138.96% for BBC. Their 0.38 correlation means their historical movements had little consistent relationship. KMID charges 0.80%/yr vs 0.79%/yr for BBC.

Performance

KMID vs. BBC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Virtus KAR Mid-Cap ETF (KMID) and Virtus LifeSci Biotech Clinical Trials ETF (BBC). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, KMID achieves a 5.02% return, which is significantly lower than BBC's 32.44% return.

KMID

• 1D: 1.27%
• 1M: 1.50%
• 6M: 1.97%
• YTD: 5.02%
• 1Y: 3.51%
• 3Y*: —
• 5Y*: —
• 10Y*: —
• ALL TIME*: 1.19%

BBC

• 1D: 4.27%
• 1M: -3.26%
• 6M: 21.02%
• YTD: 32.44%
• 1Y: 138.96%
• 3Y*: 31.60%
• 5Y*: 2.56%
• 10Y*: 9.83%
• ALL TIME*: 6.68%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison

Position	Avg. Volume Value (2W)	Avg. Volume Value (1M)	Avg. Volume Value (3M)
BBC Virtus LifeSci Biotech Clinical Trials ETF	$617.57K	$1.42M	$1.20M
KMID Virtus KAR Mid-Cap ETF	$368.95K	$294.28K	$236.43K

KMID vs. BBC - Yearly Performance Comparison

	2026 (YTD)	2025	2024
KMID Virtus KAR Mid-Cap ETF	5.02%	0.31%	-3.02%
BBC Virtus LifeSci Biotech Clinical Trials ETF	32.44%	63.77%	-18.00%

Correlation

The correlation between KMID and BBC is 0.28, which is low. Their historical price movements had little consistent relationship.

	Correlation
Correlation (1Y) Focuses on recent behavior, but can change the most.	0.28
Correlation (All Time) Calculated using the full available price history since Oct 16, 2024	0.38

KMID vs. BBC - Sectors Allocation Comparison

Sectors	KMID	BBC
Industrials	45.2%	-
Technology	18.6%	-
Healthcare	14.0%	100.0%
Financial Services	9.4%	0.8%
Consumer Cyclical	4.7%	-
Basic Materials	-	-
Communication Services	-	-
Consumer Defensive	-	-
Energy	-	-
Real Estate	-	-
Utilities	-	-

Return for Risk

KMID vs. BBC — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

KMID

KMID Risk / Return Rank: 15
KMID Sharpe Ratio Rank: 15
KMID Sortino Ratio Rank: 14
KMID Omega Ratio Rank: 14
KMID Calmar Ratio Rank: 15
KMID Martin Ratio Rank: 16

BBC

BBC Risk / Return Rank: 96
BBC Sharpe Ratio Rank: 98
BBC Sortino Ratio Rank: 95
BBC Omega Ratio Rank: 93
BBC Calmar Ratio Rank: 98
BBC Martin Ratio Rank: 96

The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

KMID vs. BBC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Virtus KAR Mid-Cap ETF (KMID) and Virtus LifeSci Biotech Clinical Trials ETF (BBC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	KMID	BBC	Difference
Sharpe ratio: Return per unit of total volatility	0.24	3.82	-3.58
Sortino ratio: Return per unit of downside risk	0.45	4.22	-3.76
Omega ratio: Gain probability vs. loss probability	1.05	1.50	-0.45
Calmar ratio: Return relative to maximum drawdown	0.33	9.26	-8.93
Martin ratio: Return relative to average drawdown	0.95	25.08	-24.13

KMID vs. BBC - Sharpe Ratio Comparison

The current KMID Sharpe Ratio is 0.24, which is lower than the BBC Sharpe Ratio of 3.82. The chart below compares the historical Sharpe Ratios of KMID and BBC, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

KMID vs. BBC - Drawdown Comparison

The maximum KMID drawdown since its inception was -18.89%, smaller than the maximum BBC drawdown of -76.85%. Use the drawdown chart below to compare losses from any high point for KMID and BBC.

Drawdown Indicators

	KMID	BBC	Difference
Max Drawdown Largest peak-to-trough decline	-18.89%	-76.85%	+57.96%
Max Drawdown (1Y) Largest decline over 1 year	-10.71%	-15.10%	+4.39%
Max Drawdown (3Y) Largest decline over 3 years	—	-54.45%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-70.92%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-76.85%	—
Current Drawdown Current decline from peak	-2.34%	-14.99%	+12.65%
Average Drawdown Average peak-to-trough decline	-5.62%	-36.86%	+31.24%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.72%	5.56%	-1.84%

Volatility

KMID vs. BBC - Volatility Comparison

The current volatility for Virtus KAR Mid-Cap ETF (KMID) is 3.91%, while Virtus LifeSci Biotech Clinical Trials ETF (BBC) has a volatility of 11.15%. This indicates that KMID experiences smaller price fluctuations and is considered to be less risky than BBC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	KMID	BBC	Difference
Volatility (1M) Calculated over the trailing 1-month period	3.91%	11.15%	-7.24%
Volatility (6M) Calculated over the trailing 6-month period	11.64%	26.45%	-14.81%
Volatility (1Y) Calculated over the trailing 1-year period	14.90%	36.65%	-21.75%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	16.74%	39.65%	-22.91%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	16.74%	37.74%	-21.00%

KMID vs. BBC - Expense Ratio Comparison

KMID has a 0.80% expense ratio, which is higher than BBC's 0.79% expense ratio.

Dividends

KMID vs. BBC - Dividend Comparison

KMID's dividend yield for the trailing twelve months is around 0.11%, less than BBC's 1.28% yield.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
BBC Virtus LifeSci Biotech Clinical Trials ETF	1.28%	1.70%	1.00%	0.34%	0.00%	0.00%	0.00%	0.00%	0.00%	2.09%	0.00%	0.51%
KMID Virtus KAR Mid-Cap ETF	0.11%	0.06%	0.05%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions

Can I hold both KMID and BBC in my portfolio?

KMID and BBC have a correlation of 0.28, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, KMID or BBC?

BBC has higher volatility (11.15%) compared to KMID (3.91%). In terms of maximum drawdown, KMID dropped -18.89% vs BBC's -76.85%.

Which ETF is better, KMID or BBC?

On 1-year performance, BBC leads with 138.96% vs 3.51% for KMID. On fees, BBC is cheaper at 0.79% per year. On volatility, KMID has been the lower-risk option at 3.91%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, KMID or BBC?

Over the 1-year period, BBC has performed better with a 138.96% return vs 3.51%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, KMID or BBC?

BBC is cheaper with a 0.79% expense ratio, compared with 0.80% for KMID.

Which ETF pays a higher dividend yield, KMID or BBC?

BBC has the higher dividend yield at 1.28%, compared with 0.11% for KMID.

What is the main difference between KMID and BBC?

KMID is categorized as Mid Cap Growth Equities, while BBC is Health & Biotech Equities. Their fees differ too: 0.80% for KMID and 0.79% for BBC.

Which has better risk-adjusted returns?

BBC currently has the higher Sharpe Ratio (3.81 vs 0.24), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.